Edwards Lifesciences (EW) Tops Q1 EPS by 5c; Issues Solid Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Edwards Lifesciences (EW) PT Raised to $125 at Leerink Partners
April 27, 2016 12:44 PM EDTLeerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted is price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $115.00) following continued strong results.
Antalffy commented, "Last night, EW reported yet another quarter of better than-expected sales -- now its 8th consecutive quarter of sales outperformance -- with 1Q16 adjusted sales of $695.6M (+18% y/y, +19% ex. FX), coming in ~$27M ahead of us and over $30M ahead of the Street. Again, stronger... More
Edwards Lifesciences (EW) PT Raised to $125 at Jefferies
April 27, 2016 8:19 AM EDTJefferies analyst Raj Denhoy reiterated a Buy rating and raised his price target on Edwards Lifesciences (NYSE: EW) to $125.00 (from $105.00) following strong results and outlook.
Denhoy commented, "EW delivered another exceptionally strong quarter. US TAVR sales were up a remarkable 64%and this was before the... More
Edwards Lifesciences (EW) PT Raised to $123 at Piper Jaffray
April 27, 2016 8:14 AM EDTPiper Jaffray analyst Brooks West raised his price target on Overweight-rated Edwards Lifesciences (NYSE: EW) to $123.00 (from $97.00) following another 'beat and raise' quarter.
West commented, "Edwards Lifesciences posted a strong beat-and-raise 1Q16 including revenue of $697.3M vs. consensus $664.2M (+20% y/y) and adjusted EPS of $0.71 vs. consensus... More
